95 related articles for article (PubMed ID: 31679309)
1. Atractylenolide III Enhances the Anti-Neoplastic Efficacy of Docetaxel in Gastric Cancer Cell by Inhibiting Fibroblast Growth Factor Receptors 1, -2, and -4 Expression.
Ji Y; Kang Z; Kang N; Zhao Y; Guo Q; Chen Y
J Environ Pathol Toxicol Oncol; 2019; 38(3):217-227. PubMed ID: 31679309
[TBL] [Abstract][Full Text] [Related]
2. Atractylenolide III predisposes miR-195-5p/FGFR1 signaling axis to exert tumor-suppressive functions in liver cancer.
Sheng L; Li J; Li N; Gong L; Liu L; Zhang Q; Li X; Luo H; Chen Z
J Food Biochem; 2021 May; 45(5):e13582. PubMed ID: 33768570
[TBL] [Abstract][Full Text] [Related]
3. FGFR1 is an independent prognostic factor and can be regulated by miR-497 in gastric cancer progression.
Xie G; Ke Q; Ji YZ; Wang AQ; Jing M; Zou LL
Braz J Med Biol Res; 2018 Nov; 52(1):e7816. PubMed ID: 30484492
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of a novel non-ATP-competitive fibroblast growth factor receptor 1 inhibitor on gastric cancer.
Xu C; Li W; Qiu P; Xia Y; Du X; Wang F; Shen L; Chen Q; Zhao Y; Jin R; Wu J; Liang G; Li X
Anticancer Drugs; 2015 Apr; 26(4):379-87. PubMed ID: 25521558
[TBL] [Abstract][Full Text] [Related]
5. Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.
Xiao Q; Zheng F; Tang Q; Wu JJ; Xie J; Huang HD; Yang XB; Hann SS
Cell Physiol Biochem; 2018; 49(4):1615-1632. PubMed ID: 30223276
[TBL] [Abstract][Full Text] [Related]
6. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.
Sahadevan K; Darby S; Leung HY; Mathers ME; Robson CN; Gnanapragasam VJ
J Pathol; 2007 Sep; 213(1):82-90. PubMed ID: 17607666
[TBL] [Abstract][Full Text] [Related]
7. Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.
Inokuchi M; Murase H; Otsuki S; Kawano T; Kojima K
World J Surg Oncol; 2017 Jan; 15(1):2. PubMed ID: 28056982
[TBL] [Abstract][Full Text] [Related]
8. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
[TBL] [Abstract][Full Text] [Related]
9. Atractylenolide II Inhibits Proliferation, Motility and Induces Apoptosis in Human Gastric Carcinoma Cell Lines HGC-27 and AGS.
Tian S; Yu H
Molecules; 2017 Nov; 22(11):. PubMed ID: 29099789
[TBL] [Abstract][Full Text] [Related]
10. Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells.
Shoji K; Teishima J; Hayashi T; Ohara S; Mckeehan WL; Matsubara A
Oncol Rep; 2014 Jul; 32(1):65-70. PubMed ID: 24839986
[TBL] [Abstract][Full Text] [Related]
11. Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.
Ye YW; Hu S; Shi YQ; Zhang XF; Zhou Y; Zhao CL; Wang GJ; Wen JG; Zong H
Oncol Rep; 2013 Dec; 30(6):2777-84. PubMed ID: 24126887
[TBL] [Abstract][Full Text] [Related]
12. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
[TBL] [Abstract][Full Text] [Related]
13. Activation of ERK and Mutual Regulation of Stat3 and SP1 Contribute to Inhibition of PDK1 Expression by Atractylenolide-1 in Human Lung Cancer Cells.
Xiao Q; Zheng F; Wu J; Tang Q; Wang W; Hann SS
Cell Physiol Biochem; 2017; 43(6):2353-2366. PubMed ID: 29073620
[TBL] [Abstract][Full Text] [Related]
14. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14.
Okuno T; Yashiro M; Masuda G; Togano S; Kuroda K; Miki Y; Hirakawa K; Ohsawa M; Wanibuchi H; Ohira M
Ann Surg Oncol; 2019 Apr; 26(4):1093-1102. PubMed ID: 30652228
[TBL] [Abstract][Full Text] [Related]
16. Neuronal expression of fibroblast growth factor receptors in zebrafish.
Rohs P; Ebert AM; Zuba A; McFarlane S
Gene Expr Patterns; 2013 Dec; 13(8):354-61. PubMed ID: 23850987
[TBL] [Abstract][Full Text] [Related]
17. In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
Guffanti F; ChilĂ R; Bello E; Zucchetti M; Zangarini M; Ceriani L; Ferrari M; Lupi M; Jacquet-Bescond A; Burbridge MF; Pierrat MJ; Damia G
Neoplasia; 2017 Jan; 19(1):35-42. PubMed ID: 27988457
[TBL] [Abstract][Full Text] [Related]
18. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
19. Atractylenolide I inhibits lipopolysaccharide-induced inflammatory responses via mitogen-activated protein kinase pathways in RAW264.7 cells.
Ji G; Chen R; Zheng J
Immunopharmacol Immunotoxicol; 2014 Dec; 36(6):420-5. PubMed ID: 25270720
[TBL] [Abstract][Full Text] [Related]
20. Different abilities of the four FGFRs to mediate FGF-1 translocation are linked to differences in the receptor C-terminal tail.
Sørensen V; Wiedlocha A; Haugsten EM; Khnykin D; Wesche J; Olsnes S
J Cell Sci; 2006 Oct; 119(Pt 20):4332-41. PubMed ID: 17003104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]